Treatment Patterns and Characteristics of Dialysis Facilities Randomly Assigned to the Medicare End-Stage Renal Disease Treatment Choices Model
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.25516
Abstract: Key Points Question How are the dialysis facilities randomly assigned to Medicare’s End-Stage Renal Disease Treatment Choices (ETC) model different from control facilities? Findings In this cross-sectional study of 6062 facilities treating 316 927 patients, patients… read more here.
Keywords: assigned medicare; dialysis; dialysis facilities; randomly assigned ... See more keywords
Randomized Controlled Trial Evaluating Levetiracetam as First-line Therapy for Seizures in Neonates
Sign Up to like & getrecommendations! Published in 2020 at "Indian Pediatrics"
DOI: 10.1007/s13312-020-1965-9
Abstract: This multicenter, randomized, blinded, controlled, trial investigated the efficacy and safety of levetiracetam compared with phenobarbital as a preferred treatment for neonatal seizures of any cause. The primary outcome variable was complete seizure freedom for… read more here.
Keywords: randomized controlled; randomly assigned; levetiracetam; controlled trial ... See more keywords
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.01308
Abstract: PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the… read more here.
Keywords: durvalumab; chemoradiotherapy; cell; pacific trial ... See more keywords
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00332
Abstract: PURPOSE CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M… read more here.
Keywords: ipilimumab versus; checkmate 651; randomly assigned; nivolumab plus ... See more keywords